Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xentuzumab + Everolimus + Exemestane in HR+/HER2- Advanced Breast Cancer
NCT02123823Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, randomised, open-label trial of xentuzumab in breast cancer (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Progression-free Survival at 30 months, Dose Limiting Toxicity at 28 days and 1 more. Started May 2014; status: completed.
02
Drugs
xentuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02123823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123823.